April 2026 in “Scientific Reports” This study presents a new automated computer vision system to objectively measure periocular hair density changes in breast cancer patients undergoing chemotherapy, demonstrating high precision in tracking individual changes and potential as a reliable tool for future clinical trials.
October 2021 in “International journal of basic and clinical pharmacology” This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.
1 citations
,
December 2019 This study found that bimatoprost eye drops significantly increased eyelash length, thickness, pigmentation, and the number of eyelashes per follicle in rabbits within one month.
38 citations
,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.
19 citations
,
July 2020 in “Journal of cancer survivorship” This review discusses the unmet supportive care needs of men and women experiencing chemotherapy-induced alopecia and reports no new results, urging healthcare providers to tailor interventions to individual patient needs.